

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00		A2	(11) International Publication Number: WO 00/58473 (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/08621			(72) Inventors; and
(22) International Filing Date: 31 March 2000 (31.03.00)			(75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US).
(30) Priority Data: 60/127,607 31 March 1999 (31.03.99) US 60/127,636 2 April 1999 (02.04.99) US 60/127,728 5 April 1999 (05.04.99) US 09/540,763 30 March 2000 (30.03.00) US			(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/127,607 (CIP) Filed on 31 March 1999 (31.03.99) US 60/127,636 (CIP) Filed on 2 April 1999 (02.04.99) US 60/127,728 (CIP) Filed on 5 April 1999 (05.04.99) US 09/540,763 (CIP) Filed on 30 March 2000 (30.03.00)			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"

(57) Abstract

The present invention provides open reading frames ORFX, encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

100 105 110
Gln Leu Lys Val Leu Leu Ser Gly Lys Asp Gly Cys Pro Ala Gln Ser
115 120 125
Cys Ala Leu Arg Gln Pro Ala Pro Arg Val Cys Gly Asp Ala Val Gly
130 135 140
Cys Ala
145

<210> 6299

<211> 1466

<212> DNA

<213> Homo sapiens

<400> 6299

ctgattccgg gctgtcatgg cgaccccaa caatctgacc cccaccaact gcagctggtg
60
gccccatctcc gcgctggaga gcgatgcggc caagccagcg gaggccccc acgctccgaa
120
ggccggccagc ccgcccattg gcccagggag agcctggttc tgtaccactg gaccagtc
180
ttcagctcgc agaaggtgcg gctggtgatc gccgagaagg gcctggtgtg cgaggagcgg
240
gacgtgagcc tgccacagag cgagcacaag gagccctgg tcatgcggct caacctggc
300
gaggaggtgc ccgtcatcat ccacccgcac aacatcatca gtgactatga ccagatcatt
360
gactatgtgg agcgcaccc tt cacaggagag cacgtggtgg ccctgatgcc cgaggtggc
420
agcctgcagc acgcacggg gctgcgtac cggagctgc tggacgcact gccccatggat
480
gcctacacgc atggctgcat cctgcattcc gagctcacca ccgactccat gatccccaaag
540
tacgcccacgg ccgagatccg cagacattt gccaatgcca ccacggacct catgaaactg
600
gaccatgaag aggagcccca gctctccgag ccctacctt ctaaacaaaa gaagctcatg
660
gccaagatct tggagcatga tcatgtgagc tacctgaaga agatcctgg ggaactggcc
720
atgggtctgg accagattga ggcggagctg gagaagagga agctggagaa cgagggcag
780
aaatgcgagc tggctctg tggctgtgcc ttcaccctcg ctgatgtcct cctggagcc
840
accctgcacc gcctcaagtt cctggactg tccaagaaat actggaaaga tggcagccgg
900
cccaacctgc agtccttctt tgagagggtc cagagacgt ttgccttccg gaaagtctg
960
ggtgacatcc acaccaccct gctgtcggcc gtcattccca atgctttccg gctggtcaag
1020
aggaaacccc catccttctt cggggcgtcc ttcctcatgg gtcaccctggg tggatggc
1080
tactttgcct actggtacct caagaaaaaa tacatctagg gccaggcctg gggcttggtg
1140
tctgactgtc ggtgtctctg tgctgtgtga ttccccgtga gctctcagta actcaactgtc
1200

tcatgaacac ttggacagcc ctccccgccc ttcgttctga gtaataatac cgtcagtgtg
 1260
 aaaacattcc gtagttttaga agtagacgtt gcaaattgctg tgactcaagg ccacggctct
 1320
 gctaaaagag agagaaggaa cgagagagag agagaaaaaa caaaaaacca gaaaaccacg
 1380
 aatgcctttt tctatcgatt tcaaggcttc aagatggaa ctgtgggaga ctgggttagg
 1440
 atctgagggg aactcttca cagggaa
 1466

<210> 6300
 <211> 372
 <212> PRT
 <213> Homo sapiens

<400> 6300
 Leu Ile Pro Gly Cys His Gly Asp Pro Gln Gln Ser Asp Pro His Gln
 1 5 10 15
 Leu Gln Leu Val Ala His Leu Arg Ala Gly Glu Arg Cys Gly Gln Ala
 20 25 30
 Ser Gly Gly Pro Arg Arg Ser Arg Gly Gly Gln Pro Ala His Trp Pro
 35 40 45
 Arg Glu Ser Leu Val Leu Tyr His Trp Thr Gln Ser Phe Ser Ser Gln
 50 55 60
 Lys Val Arg Leu Val Ile Ala Glu Lys Gly Leu Val Cys Glu Glu Arg
 65 70 75 80
 Asp Val Ser Leu Pro Gln Ser Glu His Lys Glu Pro Trp Phe Met Arg
 85 90 95
 Leu Asn Leu Gly Glu Glu Val Pro Val Ile Ile His Arg Asp Asn Ile
 100 105 110
 Ile Ser Asp Tyr Asp Gln Ile Ile Asp Tyr Val Glu Arg Thr Phe Thr
 115 120 125
 Gly Glu His Val Val Ala Leu Met Pro Glu Val Gly Ser Leu Gln His
 130 135 140
 Ala Arg Val Leu Gln Tyr Arg Glu Leu Leu Asp Ala Leu Pro Met Asp
 145 150 155 160
 Ala Tyr Thr His Gly Cys Ile Leu His Pro Glu Leu Thr Thr Asp Ser
 165 170 175
 Met Ile Pro Lys Tyr Ala Thr Ala Glu Ile Arg Arg His Leu Ala Asn
 180 185 190
 Ala Thr Thr Asp Leu Met Lys Leu Asp His Glu Glu Pro Gln Leu
 195 200 205
 Ser Glu Pro Tyr Leu Ser Lys Gln Lys Lys Leu Met Ala Lys Ile Leu
 210 215 220
 Glu His Asp Asp Val Ser Tyr Leu Lys Lys Ile Leu Gly Glu Leu Ala
 225 230 235 240
 Met Val Leu Asp Gln Ile Glu Ala Glu Leu Glu Lys Arg Lys Leu Glu
 245 250 255
 Asn Glu Gly Gln Lys Cys Glu Leu Trp Leu Cys Gly Cys Ala Phe Thr
 260 265 270
 Leu Ala Asp Val Leu Leu Gly Ala Thr Leu His Arg Leu Lys Phe Leu
 275 280 285
 Gly Leu Ser Lys Lys Tyr Trp Glu Asp Gly Ser Arg Pro Asn Leu Gln

290 295 300
Ser Phe Phe Glu Arg Val Gln Arg Arg Phe Ala Phe Arg Lys Val Leu
305 310 315 320
Gly Asp Ile His Thr Thr Leu Leu Ser Ala Val Ile Pro Asn Ala Phe
325 330 335
Arg Leu Val Lys Arg Lys Pro Pro Ser Phe Phe Gly Ala Ser Phe Leu
340 345 350
Met Gly Ser Leu Gly Gly Met Gly Tyr Phe Ala Tyr Trp Tyr Leu Lys
355 360 365
Lys Lys Tyr Ile
370

<210> 6301
<211> 911
<212> DNA
<213> Homo sapiens

<400> 6301
nnacgggtt tagaaaaaca agaattacag cagccaacct atgttgcctt gagttacata
60
aatagattca tgacagatgc tgccggcga gagcaggagt ccctaaagaa gaagattcag
120
ccgaagctct cgtcgactct gtccagctca gtgtctcgag ggaatgtgtc cactccccc
180
cgccacagca gtgaaaggct tactcccccgtgaccccac ccattcacccc ctccctttca
240
ttccgcagca gcactccgac aggcagcgag tatgacgagg aggaggtgga ctatgaggag
300
tcggacagcg atgagtcctg gaccacagag agtgccatca gtccgaagc catcctcagc
360
tccatgtgca tgaatggagg ggaagagaag cctttgcct gcccagttcc tggatgtaaa
420
aagagataca agaatgtgaa tggcataaag tatcacgcta agaatggtca cagaacacag
480
attcgtgtcc gcaaaccatt caagtgtcgc tgtggaaaga gttacaagac agctcagggc
540
ctggggcacc acacaatcaa ttccatccc ccgggtgtcgg ctgagattat caggaagatg
600
cagcaataac atgctggtca taactgtgcc aagaaatcct caccagcgt tgctgattt
660
gaaaacagcc acctttttc aggggaagca tttagcaacc cttaaagaa aaagaattaa
720
atgcatgctt taaatttttt ctgtatgtt ggaatgtatgt atctttgtatgtt
780
tttgtacatt tgcacatgtta atcatcatac ccattttcat tactttgata taaggtgcta
840
aacaaaaaaaaa gctctagggtt cttcagcaca ttcccccaa aacaaaataa aattgagggc
900
atgttgcaaa a
911

<210> 6302
<211> 202
<212> PRT

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2 n , wherein n is any integer 1-3161, or the complement thereof.
2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 n , wherein n is any integer 1-3161, or the complement thereof.
3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n , wherein n is any integer 1-3161, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n .
4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2 n , wherein n is any integer 1-3161.
5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprise the sequence of nucleotides selected from the group consisting of SEQ ID NO:2 n -1, wherein n is any integer 1-3161, or the complement thereof.
6. An oligonucleotide less than 100 nucleotides in length and comprising at least contiguous nucleotides selected from the group consisting of SEQ ID NO:2 n -1, wherein n is a integer 1-3161, or the complement thereof.
7. A vector comprising the nucleic acid molecule of claim 1.

compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

17. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample.

18. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

19. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a ORFX-associated disorder, wherein said therapeutic is selected from the group consisting of:

- a) the nucleic acid of claim 1;
- b) the polypeptide of claim 10; and
- c) the antibody of claim 12.

20. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) contacting a test compound with the polypeptide of claim 10; and
- b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;

wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates the presence of or predisposition to said disease in said subject.

26. The method of claim 25, wherein said subject is a human.

27. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject a polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. The method of claim 27, wherein said subject is a human.

29. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject a nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said pathological condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject an antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological condition.

32. The method of claim 31, wherein said subject is a human.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 October 2000 (05.10.2000)

PCT

(10) International Publication Number
WO 00/58473 A3

(51) International Patent Classification⁷: C12N 15/12, C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N 15/11, 15/62, A01K 67/027, A61K 38/00

Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LEACH, Martin [GB/US]; 884 School Street, Webster, MA 01570 (US).

(21) International Application Number: PCT/US00/08621

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(22) International Filing Date: 31 March 2000 (31.03.2000)

(25) Filing Language:

English

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language:

English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:

60/127,607	31 March 1999 (31.03.1999)	US
60/127,636	2 April 1999 (02.04.1999)	US
60/127,728	5 April 1999 (05.04.1999)	US
09/540,763	30 March 2000 (30.03.2000)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/127,607 (CIP)
Filed on	31 March 1999 (31.03.1999)
US	60/127,636 (CIP)
Filed on	2 April 1999 (02.04.1999)
US	60/127,728 (CIP)
Filed on	5 April 1999 (05.04.1999)
US	09/540,763 (CIP)
Filed on	30 March 2000 (30.03.2000)

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

(71) Applicant (for all designated States except US): CURA-GEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).

(88) Date of publication of the international search report:
25 January 2001

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHIMKETS,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/58473 A3

(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"

(57) Abstract: The present invention provides open reading frames encoding isolated polypeptides, as well as polynucleotides encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

INTERNATIONAL SEARCH REPORT

Internat'l Application No
PCT/US 00/08621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	M.D. ADAMS ET AL.: "The genome sequence of <i>Drosophila melanogaster</i> ." SCIENCE, vol. 287, 24 March 2000 (2000-03-24), pages 2185-2195, XP002144875 the whole document -----	6

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claim : 1 to 32 partially

Isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from a group consisting of SEQ ID NO 2n wherein n is 1, oligonucleotides less than 100 nucleotides in length and comprising at least 6 contiguous nucleotides from the above sequence, polypeptides encoded by said nucleotides, antibodies that bind to said polypeptide, pharmaceutical composition comprising said polypeptide and methods of detection, screening, therapeutic uses involving said polypeptide.

2. Claim : .

Inventions 2 to 3161

claims 1 to 32 partially :

Isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from a group consisting of SEQ ID NO 2n wherein n is 2 to 3161, oligonucleotides less than 100 nucleotides in length and comprising at least 6 contiguous nucleotides from the above sequence, polypeptides encoded by said nucleotides, antibodies that bind to said polypeptide, pharmaceutical composition comprising said polypeptide and methods of detection, screening, therapeutic uses involving said polypeptide.